RxDoctor Payments Data

Marsha Kavanagh, MD

Ophthalmology · Portsmouth, NHNPI 1467403659

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Amgen at 51.6% of the total. That places this record below the midpoint for ophthalmology clinicians in NH, where the typical reported total is $750.

$371in general payments, 2019–2025

Across 20 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$191
  • Aerie Pharmaceuticals, Inc.$64
  • Oyster Point Pharma, Inc.$27
  • Novartis$25
  • Regeneron Healthcare Solutions, Inc.$23
  • AbbVie$21
  • plus $21 from 1 others

What the payments were for

  • Food & beverage$371100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$371 in reported general payments places this provider in the 35th percentile of 80 ophthalmology providers in New Hampshire.

See all ophthalmology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$353,959
Medicare patients
1,276
Services billed
5,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine38$39,813
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha435$4,221
Tobramycin-DexamethasoneTobramycin/Dexamethasone47$3,557
Prednisolone Acetate31$1,411
ValacyclovirValacyclovir Hcl11$927
MoxifloxacinMoxifloxacin Hcl28$495
ErythromycinErythromycin Base59$491
Doxycycline Hyclate19$387
Cephalexin41$234
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim22$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$21$39,81338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 80 ophthalmology providers in New Hampshire.

Other ophthalmology in Portsmouth

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →